{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:54:29Z","timestamp":1793123669712,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The proton pump inhibitor omeprazole is administered to dogs with gastroduodenal ulceration or oesophagitis, whereas the neurokinin-1 receptor antagonist maropitant citrate is licensed as an antiemetic drug. In people, omeprazole is overprescribed in hospitals, increasing the risk of adverse effects and imposing unnecessary costs in healthcare. To investigate the use of omeprazole and maropitant in our veterinary specialist hospital, we conducted a prospective observational study in its Medicine and Surgery wards, recording patient data and obtaining contemporaneous information from clinicians about their reasons for administering either drug. In doing so, we find omeprazole and maropitant are administered to a large proportion of dogs, including to many of those with no presenting signs suggestive of gastrointestinal disease. We find prescribing clinicians consider both drugs safe but often underestimate their financial cost. We find the stated reasons and objective predictors of administration of both drugs vary according to clinical setting but that these modalities yield concordant results. Reviewing the manner of administration and stated indications for use of both drugs, we find omeprazole is often administered outside dosing recommendations, and both drugs are frequently administered for aims that are unlikely to be achieved when considering their known biological effects in dogs. In conclusion, our work reveals probable overprescribing of omeprazole and maropitant citrate in hospitalised dogs, highlighting a need for initiatives to decrease inappropriate prescribing.<\/jats:p>","DOI":"10.1038\/s41598-020-72950-3","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T10:02:43Z","timestamp":1601028163000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prospective observational study of the use of omeprazole and maropitant citrate in veterinary specialist care"],"prefix":"10.1038","volume":"10","author":[{"given":"Rachel","family":"McCormack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Olley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Glanemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Swann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"72950_CR1","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/vr.165.15.436","volume":"165","author":"M Cariou","year":"2009","unstructured":"Cariou, M., Lipscomb, V. J., Brockman, D. J., Gregory, S. P. & Baines, S. J. Spontaneous gastroduodenal perforations in dogs: a retrospective study of 15 cases. Vet. Rec. 165, 436\u2013441 (2009).","journal-title":"Vet. Rec."},{"key":"72950_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1939-1676.1989.tb00863.x","volume":"3","author":"ME Stanton","year":"1989","unstructured":"Stanton, M. E. & Bright, R. M. Gastroduodenal ulceration in dogs. Retrospective study of 43 cases and literature review. J. Vet. Intern. Med. 3, 238\u2013244 (1989).","journal-title":"J. Vet. Intern. Med."},{"key":"72950_CR3","first-page":"448","volume":"29","author":"DH Shaw","year":"1988","unstructured":"Shaw, D. H. Gastrinoma (Zollinger\u2013Ellison syndrome) in the dog and cat. Can. Vet. J. 29, 448\u2013452 (1988).","journal-title":"Can. Vet. J."},{"key":"72950_CR4","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1111\/jvim.15337","volume":"32","author":"SL Marks","year":"2018","unstructured":"Marks, S. L., Kook, P. H., Papich, M. G., Tolbert, M. K. & Willard, M. D. ACVIM consensus statement: support for rational administration of gastrointestinal protectants to dogs and cats. J. Vet. Intern. Med. 32, 1823\u20131840 (2018).","journal-title":"J. Vet. Intern. Med."},{"key":"72950_CR5","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1748-5827.2009.00818.x","volume":"50","author":"A Panti","year":"2009","unstructured":"Panti, A. et al. The effect of omeprazole on oesophageal pH in dogs during anaesthesia. J. Small Anim. Pract. 50, 540\u2013544 (2009).","journal-title":"J. Small Anim. Pract."},{"key":"72950_CR6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1939-1676.2012.00929.x","volume":"26","author":"AC Zacuto","year":"2012","unstructured":"Zacuto, A. C. et al. The influence of esomeprazole and cisapride on gastroesophageal reflux during anesthesia in dogs. J. Vet. Intern. Med. 26, 518\u2013525 (2012).","journal-title":"J. Vet. Intern. Med."},{"key":"72950_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/archinternmed.2010.64","volume":"170","author":"MH Katz","year":"2010","unstructured":"Katz, M. H. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch. Intern. Med. 170, 747\u2013748 (2010).","journal-title":"Arch. Intern. Med."},{"key":"72950_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","volume":"153","author":"MF Vaezi","year":"2017","unstructured":"Vaezi, M. F., Yang, Y. X. & Howden, C. W. Complications of proton pump inhibitor therapy. Gastroenterology 153, 35\u201348 (2017).","journal-title":"Gastroenterology"},{"key":"72950_CR9","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","volume":"296","author":"YX Yang","year":"2006","unstructured":"Yang, Y. X., Lewis, J. D., Epstein, S. & Metz, D. C. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296, 2947\u20132953 (2006).","journal-title":"JAMA"},{"key":"72950_CR10","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/j.1365-2036.2011.04874.x","volume":"34","author":"C Bavishi","year":"2011","unstructured":"Bavishi, C. & Dupont, H. L. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment. Pharmacol. Ther. 34, 1269\u20131281 (2011).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"72950_CR11","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1001\/jama.2013.280490","volume":"310","author":"JR Lam","year":"2013","unstructured":"Lam, J. R., Schneider, J. L., Zhao, W. & Corley, D. A. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 310, 2435\u20132442 (2013).","journal-title":"JAMA"},{"key":"72950_CR12","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/17512433.2018.1531703","volume":"11","author":"V Savarino","year":"2018","unstructured":"Savarino, V. et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev. Clin. Pharmacol. 11, 1123\u20131134 (2018).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"72950_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/SMJ.0b013e3181ce0e7a","volume":"103","author":"R Gupta","year":"2010","unstructured":"Gupta, R. et al. Overuse of acid suppression therapy in hospitalized patients. South. Med. J. 103, 207\u2013211 (2010).","journal-title":"South. Med. J."},{"key":"72950_CR14","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1111\/j.1572-0241.2006.00839.x","volume":"101","author":"JJ Heidelbaugh","year":"2006","unstructured":"Heidelbaugh, J. J. & Inadomi, J. M. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am. J. Gastroenterol. 101, 2200\u20132205 (2006).","journal-title":"Am. J. Gastroenterol."},{"key":"72950_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/jhm.1901","volume":"7","author":"M Reid","year":"2012","unstructured":"Reid, M. et al. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J. Hosp. Med. 7, 421\u2013425 (2012).","journal-title":"J. Hosp. Med."},{"key":"72950_CR16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.18553\/jmcp.2010.16.2.122","volume":"16","author":"L Thomas","year":"2010","unstructured":"Thomas, L. et al. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J. Manag. Care Pharm. 16, 122\u2013129 (2010).","journal-title":"J. Manag. Care Pharm."},{"key":"72950_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/clpt.2008.224","volume":"85","author":"SN Hilmer","year":"2009","unstructured":"Hilmer, S. N. & Gnjidic, D. The effects of polypharmacy in older adults. Clin. Pharmacol. Ther. 85, 86\u201388 (2009).","journal-title":"Clin. Pharmacol. Ther."},{"key":"72950_CR18","first-page":"41","volume":"8","author":"BL Hay Kraus","year":"2017","unstructured":"Hay Kraus, B. L. Spotlight on the perioperative use of maropitant citrate. Vet. Med. (Auckl) 8, 41\u201351 (2017).","journal-title":"Vet. Med. (Auckl)"},{"key":"72950_CR19","doi-asserted-by":"publisher","first-page":"495704","DOI":"10.1155\/2015\/495704","volume":"2015","author":"S Garcia-Recio","year":"2015","unstructured":"Garcia-Recio, S. & Gascon, P. Biological and pharmacological aspects of the NK1-receptor. Biomed. Res. Int. 2015, 495704 (2015).","journal-title":"Biomed. Res. Int."},{"key":"72950_CR20","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1111\/j.1939-1676.2010.0611.x","volume":"24","author":"SE Rau","year":"2010","unstructured":"Rau, S. E., Barber, L. G. & Burgess, K. E. Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs. J. Vet. Intern. Med. 24, 1452\u20131457 (2010).","journal-title":"J. Vet. Intern. Med."},{"key":"72950_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2460\/ajvr.68.1.48","volume":"68","author":"VA de la Puente-Redondo","year":"2007","unstructured":"de la Puente-Redondo, V. A., Tilt, N., Rowan, T. G. & Clemence, R. G. Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. Am. J. Vet. Res. 68, 48\u201356 (2007).","journal-title":"Am. J. Vet. Res."},{"key":"72950_CR22","first-page":"35","volume":"58","author":"AM Lorenzutti","year":"2017","unstructured":"Lorenzutti, A. M. et al. A comparison between maropitant and metoclopramide for the prevention of morphine-induced nausea and vomiting in dogs. Can. Vet. J. 58, 35\u201338 (2017).","journal-title":"Can. Vet. J."},{"key":"72950_CR23","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1136\/vr.161.13.444","volume":"161","author":"HA Benchaoui","year":"2007","unstructured":"Benchaoui, H. A. et al. Efficacy of maropitant for preventing vomiting associated with motion sickness in dogs. Vet. Rec. 161, 444\u2013447 (2007).","journal-title":"Vet. Rec."},{"key":"72950_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.tvjl.2014.10.007","volume":"203","author":"H Kenward","year":"2015","unstructured":"Kenward, H., Pelligand, L., Savary-Bataille, K. & Elliott, J. Nausea: current knowledge of mechanisms, measurement and clinical impact. Vet. J. 203, 36\u201343 (2015).","journal-title":"Vet. J."},{"key":"72950_CR25","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.vaa.2016.10.006","volume":"44","author":"A Swallow","year":"2017","unstructured":"Swallow, A., Rioja, E., Elmer, T. & Dugdale, A. The effect of maropitant on intraoperative isoflurane requirements and postoperative nausea and vomiting in dogs: a randomized clinical trial. Vet. Anaesth. Analg. 44, 785\u2013793 (2017).","journal-title":"Vet. Anaesth. Analg."},{"key":"72950_CR26","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12917-017-1156-7","volume":"13","author":"H Kenward","year":"2017","unstructured":"Kenward, H., Elliott, J., Lee, T. & Pelligand, L. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. BMC Vet. Res. 13, 244 (2017).","journal-title":"BMC Vet. Res."},{"key":"72950_CR27","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/jvim.15463","volume":"33","author":"JW Swann","year":"2019","unstructured":"Swann, J. W. et al. ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs. J. Vet. Intern. Med. 33, 1141\u20131172 (2019).","journal-title":"J. Vet. Intern. Med."},{"key":"72950_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.prevetmed.2017.02.014","volume":"140","author":"CA Pugh","year":"2017","unstructured":"Pugh, C. A. et al. Incidence rates and risk factor analyses for owner reported vomiting and diarrhoea in Labrador retrievers\u2014findings from the Dogslife cohort. Prev. Vet. Med. 140, 19\u201329 (2017).","journal-title":"Prev. Vet. Med."},{"key":"72950_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/vec.12434","volume":"26","author":"JW Swann","year":"2016","unstructured":"Swann, J. W., Maunder, C. L., Roberts, E., McLauchlan, G. & Adamantos, S. Prevalence and risk factors for development of hemorrhagic gastro-intestinal disease in veterinary intensive care units in the United Kingdom. J. Vet. Emerg. Crit. Care (San Antonio) 26, 419\u2013427 (2016).","journal-title":"J. Vet. Emerg. Crit. Care (San Antonio)"},{"key":"72950_CR30","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1574-6941.2012.01331.x","volume":"80","author":"JF Garcia-Mazcorro","year":"2012","unstructured":"Garcia-Mazcorro, J. F. et al. Effect of the proton pump inhibitor omeprazole on the gastrointestinal bacterial microbiota of healthy dogs. FEMS Microbiol. Ecol. 80, 624\u2013636 (2012).","journal-title":"FEMS Microbiol. Ecol."},{"key":"72950_CR31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","volume":"65","author":"MA Jackson","year":"2016","unstructured":"Jackson, M. A. et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 65, 749\u2013756 (2016).","journal-title":"Gut"},{"key":"72950_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1939-1676.2010.0651.x","volume":"25","author":"K Tolbert","year":"2011","unstructured":"Tolbert, K. et al. Efficacy of oral famotidine and 2 omeprazole formulations for the control of intragastric pH in dogs. J. Vet. Intern. Med. 25, 47\u201354 (2011).","journal-title":"J. Vet. Intern. Med."},{"key":"72950_CR33","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/vaa.12120","volume":"41","author":"RA Johnson","year":"2014","unstructured":"Johnson, R. A. Maropitant prevented vomiting but not gastroesophageal reflux in anesthetized dogs premedicated with acepromazine-hydromorphone. Vet. Anaesth. Analg. 41, 406\u2013410 (2014).","journal-title":"Vet. Anaesth. Analg."},{"key":"72950_CR34","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/jsap.12914","volume":"59","author":"BM Kaye","year":"2018","unstructured":"Kaye, B. M., Rutherford, L., Perridge, D. J. & Ter Haar, G. Relationship between brachycephalic airway syndrome and gastrointestinal signs in three breeds of dog. J. Small Anim. Pract. 59, 670\u2013673 (2018).","journal-title":"J. Small Anim. Pract."},{"key":"72950_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1748-5827.2005.tb00320.x","volume":"46","author":"CM Poncet","year":"2005","unstructured":"Poncet, C. M. et al. Prevalence of gastrointestinal tract lesions in 73 brachycephalic dogs with upper respiratory syndrome. J. Small Anim. Pract. 46, 273\u2013279 (2005).","journal-title":"J. Small Anim. Pract."},{"key":"72950_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5326\/JAAHA-MS-6281","volume":"53","author":"SL Shaver","year":"2017","unstructured":"Shaver, S. L. et al. Evaluation of gastroesophageal reflux in anesthetized dogs with brachycephalic syndrome. J. Am. Anim. Hosp. Assoc. 53, 24\u201331 (2017).","journal-title":"J. Am. Anim. Hosp. Assoc."},{"key":"72950_CR37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/08941930500248656","volume":"18","author":"RP Boesch","year":"2005","unstructured":"Boesch, R. P. et al. Relationship between upper airway obstruction and gastroesophageal reflux in a dog model. J. Invest. Surg. 18, 241\u2013245 (2005).","journal-title":"J. Invest. Surg."},{"key":"72950_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1748-5827.2006.00057.x","volume":"47","author":"CM Poncet","year":"2006","unstructured":"Poncet, C. M., Dupre, G. P., Freiche, V. G. & Bouvy, B. M. Long-term results of upper respiratory syndrome surgery and gastrointestinal tract medical treatment in 51 brachycephalic dogs. J. Small Anim. Pract. 47, 137\u2013142 (2006).","journal-title":"J. Small Anim. Pract."},{"key":"72950_CR39","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/jsap.12948","volume":"59","author":"F Downing","year":"2018","unstructured":"Downing, F. & Gibson, S. Anaesthesia of brachycephalic dogs. J. Small Anim. Pract. 59, 725\u2013733 (2018).","journal-title":"J. Small Anim. Pract."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72950-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72950-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72950-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T19:27:33Z","timestamp":1670354853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72950-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["72950"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-72950-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"22 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15727"}}